Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
527.00    16.00 (3.13%)
Bid:
525.00
Ask:
525.50
Spread: 0.50 (0.095%)
Market Cap: £1.43b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

AGM Trading Update

21 Mar 2016 11:00

RNS Number : 7407S
Chemring Group PLC
21 March 2016
 

21 MARCH 2016

 

CHEMRING GROUP PLC

ANNUAL GENERAL MEETING TRADING UPDATE

 

Chemring Group PLC ("Chemring" or "the Group") today issues an update on current trading and outlook, at the time of the Group's Annual General Meeting.

 

Current trading

Revenue during the three month period to 31 January 2016 was £82.9 million, compared with £61.5 million in the same period last year, with increases in each of the Group's three operating segments. As reported in the results announcement issued on 21 January 2016, Q1 FY16 trading performance was below management's expectations due to a lower margin sales mix, customer acceptance delays, and specific production and contract finalisation issues.

 

The order book at 31 January 2016 was £593.8 million (31 October 2015: £569.6 million).

 

The 40mm ammunition order for an end user in the Middle East continues to progress towards initial revenues. A further announcement will be made once the advance payment has been received.

 

Current financial position

Net debt at 31 December 2015 was £195 million. Net debt at 31 January 2016 was £198.4 million (31 January 2015: £162.1 million, 31 October 2015: £154.3 million). The recent strengthening of the US dollar increased the translated value of the Group's debt in the three month period by £14.1 million. Cash flows in the three month period were impacted by the weaker trading and increased working capital, combined with normal seasonal effects, however these are expected to unwind in the second half of FY16. Since 31 January 2016, the Group has received £75.2 million net proceeds of the Rights Issue and is in the process of offering a proportion of the proceeds to loan note holders.

 

Board changes

Ian Much will retire at today's Annual General Meeting. Daniel Dayan joined the Board on 7 March 2016 and will succeed him as Chairman of the Remuneration Committee. The process of appointing a successor to the Chairman, Peter Hickson, continues to progress.

 

Outlook

The Board's expectations for trading and net debt for the full year remain unchanged. The continued delayed start to the 40mm ammunition contract and revenue mix have consequently led to an increased weighting in both profit and cashflow towards the second half.

 

-ENDS-

 

 

For further information:

 

Michael Flowers Group Chief Executive, Chemring Group PLC 01794 833901

Steve Bowers Group Finance Director, Chemring Group PLC 01794 833901

Rupert Pittman Group Director of Communications and 01794 833901

Investor Relations, Chemring Group PLC

 

James White MHP Communications 0203 128 8100

 

Cautionary statement

 

This announcement contains unaudited information based on management accounts and forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

 

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

 

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

 

· Chemring is a global business that specialises in the manufacture of high technology products and services to the aerospace, defence and security markets

· Employing approximately 3,000 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries worldwide

· Chemring is now organised under three strategic product segments: Countermeasures, Sensors & Electronics, and Energetic Systems

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, mission and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development, Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBGGDXDSDBGLB
Date   Source Headline
8th Aug 20237:00 amRNSTransaction in Own Shares
7th Aug 20237:00 amRNSTransaction in Own Shares
4th Aug 20234:16 pmRNSDirector/PDMR Shareholding
4th Aug 20234:15 pmRNSDirector/PDMR Shareholding
4th Aug 20237:00 amRNSTransaction in Own Shares
3rd Aug 20237:00 amRNSTransaction in Own Shares
2nd Aug 20237:00 amRNSTransaction in Own Shares
1st Aug 20239:26 amRNSTotal Voting Rights
1st Aug 20237:00 amRNSShare buyback programme
3rd Jul 20237:00 amRNSDirector/PDMR Shareholding
21st Jun 20239:47 amRNSBlock listing Interim Review
13th Jun 20237:00 amRNSAppointment of non-executive director
6th Jun 20237:00 amRNSHalf year results to 30 April 2023
1st Jun 202310:28 amRNSTotal Voting Rights
24th May 20237:00 amRNSAppointment of Chief Financial Officer
2nd May 20232:51 pmRNSTotal Voting Rights
20th Apr 202312:02 pmRNSDirector Declaration
3rd Apr 20239:25 amRNSTotal Voting Rights
29th Mar 20237:00 amRNSContract Award
28th Mar 20233:29 pmRNSHolding(s) in Company
16th Mar 20234:23 pmRNSDoc re. Ordinary & Special Resolutions
15th Mar 20233:11 pmRNSResult of AGM
15th Mar 20237:00 amRNSAGM Trading Update
1st Mar 202310:33 amRNSTotal Voting Rights
24th Feb 20239:07 amRNSDirector Declaration
1st Feb 202310:10 amRNSTotal Voting Rights
24th Jan 20233:09 pmRNSDirector/PDMR Shareholding
23rd Jan 20237:00 amRNSDirectorate Change
16th Jan 202310:44 amRNSNotice of AGM
9th Jan 20237:10 amRNSDirector Declaration
3rd Jan 202310:54 amRNSTotal Voting Rights
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20223:41 pmRNSBlock listing Interim Review
14th Dec 202212:31 pmRNSDirector/PDMR Shareholding
14th Dec 202212:28 pmRNSDirector/PDMR Shareholding
14th Dec 202212:27 pmRNSDirector/PDMR Shareholding
14th Dec 202212:25 pmRNSDirector/PDMR Shareholding
14th Dec 202212:23 pmRNSDirector/PDMR Shareholding
14th Dec 202212:20 pmRNSDirector/PDMR Shareholding
13th Dec 20227:00 amRNSFinal Results
1st Dec 202210:01 amRNSTotal Voting Rights
11th Nov 20222:30 pmRNSHolding(s) in Company
1st Nov 202210:02 amRNSTotal Voting Rights
18th Oct 20224:17 pmRNSHolding(s) in Company
6th Oct 20227:00 amRNSTrading Update
3rd Oct 20221:55 pmRNSAdditional Listings
3rd Oct 20229:36 amRNSTotal Voting Rights
12th Sep 20229:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.